Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
Leendert H Zaaijer(Erasmus MC Cancer Institute), Mieke Kriege, B.F.M. Slangen(Maastricht University Medical Centre), Hans F. A. Vasen(Leiden University Medical Center), Luc R.C.W. van Lonkhuijzen(University of Amsterdam), Joanne A. de Hullu(Radboud University Nijmegen), Marc van Beurden(Oncode Institute), Ronald P. Zweemer(Cancer Genomics Centre), P.M.L.H. Vencken(Erasmus MC), Helena C. van Doorn, Muriel A. Adank(The Netherlands Cancer Institute), Katja N. Gaarenstroom(Radboud University Nijmegen), Caroline Seynaeve(Radboud University Nijmegen), Marian J.E. Mourits(Radboud University Nijmegen)
Cited by 4
Related Papers
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
|New England Journal of Medicine|2004|1.7k
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k